How much funding has CurifyLabs raised?

CurifyLabs has raised $19M in total funding. Key investors include Lifeline Ventures (Seed lead), Springvest (Series A lead), Pharmacy Pension Fund (Apteekkien Eläkekassa), Business Finland (grants and €1M deep tech loan in Series A), European Innovation Council (EIC Accelerator €2.5M grant).

Who is the CEO of CurifyLabs?

Charlotta Topelius is the CEO of CurifyLabs. The company was founded in 2021.

Where is CurifyLabs located?

CurifyLabs is headquartered in Helsinki, Finland.

What funding stage is CurifyLabs at?

CurifyLabs is currently at the Active stage.

How many employees does CurifyLabs have?

CurifyLabs has approximately 11-50 employees.

CurifyLabs

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

HardwareHelsinki, FinlandFounded 2021· One of 1738 Hardware companies tracked by AMPulse

An automated 3D printing platform designed for personalized medicine, enabling pharmacies and hospitals to manufacture tailored drug dosages on-site.

CEO / Founder: Charlotta Topelius
Team Size: 11-50
Stage: Active
Total Funding: $19M
Latest Round: Series A
Key Investors: Lifeline Ventures (Seed lead), Springvest (Series A lead), Pharmacy Pension Fund (Apteekkien Eläkekassa), Business Finland (grants and €1M deep tech loan in Series A), European Innovation Council (EIC Accelerator €2.5M grant)

Technology & Products

Key Products

PharmaPrinter Aurum: Next-generation 3D printer for pharmaceutical compounding that makes compounding up to 9x faster than manual processes. Features integrated quality control, compact design, and supports multiple dosage forms including troches, films, gel tablets, suppositories, and capsules. Part of the Compounding System Solution (CSS) combining proprietary software, GMP-manufactured excipients, and advanced 3D printing technology.

Technological Advantage

Utilizes a proprietary 'Tailored Dose' technology that combines hardware, software, and validated ink formulations, allowing for the production of complex drug combinations and specific release profiles that are impossible with traditional tableting.

Differentiation

Value Proposition

Replaces manual, error-prone compounding processes with an automated 'mini-factory' approach, ensuring precise dosage customization, improved patient safety, and reduced pharmaceutical waste.

How They Differentiate

Proprietary GMP-grade Pharma Inks and an end-to-end automated 'MiniLab' system (CSS) that integrates hardware, software, and validated formulations for on-site pharmacy and hospital use.

Market & Competition

Target Customers

Compounding pharmacies, hospital pharmacies, veterinary clinics, and pharmaceutical research institutions.

Industry Verticals

["Healthcare","Pharmaceuticals","Veterinary Medicine","Personalized Medicine"]

Competitors

Aprecia Pharmaceuticals; FabRx; CraftHealth

Growth & Milestones

Growth Metrics

Tripled company revenue in 2024 and reached a milestone of 26,000 tablets produced by customers across 8 European countries.

Major Milestones

["Launched the next-generation PharmaPrinter Aurum in January 2026","Secured €6.7M Series A funding led by Springvest in May 2025","Partnered with APL Sweden to improve pediatric medicine administration in September 2024","Launched the first-ever GMP-manufactured Pharma Inks for 3D printing in October 2023","Winner of the 2025 'Productive Idea' (Tuottava Idea) award by JCI Finland"]

Notable Customers

Apotek Produktion & Laboratorier (APL) - Sweden; The Woodlands Compounding Pharmacy - USA; iGalenici - Italy; Johannes Gutenberg University Mainz Hospital Pharmacy

https://curifylabs.com

Recent coverage of CurifyLabs

CurifyLabs unveiled the PharmaPrinter Aurum, an AM system making pharmaceutical compounding 9x faster than manual methods.Jan 14, 2026

Why this company matters

CurifyLabs addresses the inefficiencies and error risks of manual pharmaceutical compounding by offering an automated 3D printing platform designed for on-site personalized medicine. The company's system transitions compounding from a craft to a digital, GMP-compliant process, enabling pharmacies and hospitals to produce customized drug dosages with precision and reduced waste.

The core offering is the PharmaPrinter Aurum, a next-generation 3D printer that is part of the Compounding System Solution (CSS). This integrated system combines proprietary software, GMP-manufactured Pharma Inks, and advanced 3D printing to produce multiple dosage forms including troches, films, gel tablets, suppositories, and capsules. The 'Tailored Dose' technology allows for complex drug combinations and specific release profiles that are not achievable with traditional tableting.

Target customers include compounding pharmacies, hospital pharmacies, veterinary clinics, and pharmaceutical research institutions. Notable adopters include Apotek Produktion & Laboratorier (APL) in Sweden, The Woodlands Compounding Pharmacy in the USA, iGalenici in Italy, and Johannes Gutenberg University Mainz Hospital Pharmacy. The company tripled revenue in 2024 and reached 26,000 tablets produced across eight European countries.

CurifyLabs differentiates through its proprietary GMP-grade Pharma Inks and end-to-end automated MiniLab system, which integrates hardware, software, and validated formulations. Competitors include Aprecia Pharmaceuticals, FabRx, and CraftHealth. The company has raised €17.6M from investors including Lifeline Ventures, Springvest, the Pharmacy Pension Fund, Business Finland, and the European Innovation Council.